Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

Key facts

Sponsor

CSL Behring

Principal Investigator

Stephen Jolles, MD

University Hospital of Wales, Cardiff, UK

Intervention

Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)(biological)

Enrollment

51 enrolled

Eligibility

2-65 years · All sexes

Timeline

2007 – 2009

Study locations (19)

• Study site, Paris, France
• Study site, Berlin, Germany
• Study site, Düsseldorf, Germany
• Study site, Freiburg im Breisgau, Germany
• Study site, Hanover, Germany
• Study site, Leipzig, Germany
• Study site, Mainz, Germany
• Study site, Munich, Germany
• Study site, Brescia, Italy
• Study site, Warsaw, Poland
• Study site, Bucharest, Romania
• Study site, Cluj-Napoca, Romania
• Study site, Timișoara, Romania
• Study site, Barcelona, Spain
• Study site, Seville, Spain
• +4 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for OBSOLETE: Common variable immunodeficiency due to TNFR deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT05193552
  Usage of Spirometry in Managing IgG Therapy in CVID with Airway Disease
  University of Alabama at Birmingham
• ENROLLING BY INVITATIONPHASE2NCT05593588
  Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency
  Avni Joshi
• RECRUITINGPHASE2NCT02579967
  Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
  National Cancer Institute (NCI)

See all trials for OBSOLETE: Common variable immunodeficiency due to TNFR deficiency →